Skip to main content

Sorg Elaine K.'s Form 4 filing

AbbVie Inc. (ABBV) · filed Apr 5, 2023

Accession no.
0001415889-23-006301
Filed
Apr 5, 2023
Trade date
Apr 3, 2023
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $2.40M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Sorg Elaine K.CIK 0001832571Officer (SVP, US COMMERCIAL OPERATIONS)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Apr 3, 2023Common Stock, $0.01 par valueMOption exerciseAcquired+15,002$93.50+$1,402,68757,831Direct
Apr 3, 2023Common Stock, $0.01 par valueSSaleDisposed−15,002$160.03−$2,400,770.0642,829Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Apr 3, 2023Common StockMOption exerciseDisposed−15,002$93.50−$1,402,6870Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Remarks

The option exercise and sale transactions were made pursuant to a previously adopted plan complying with Rule 10b5-1(c).

Read the full filing on SEC EDGAR (opens in a new tab)